Galien week of innovation

Galien Week of Innovation 2022

OCT. 24-28

Galien Medal
BIOTECH - Tuesday Oct. 25


11 AM - 12 PM ET

What is the underlying science behind clinical progress in therapies that promise a genetics-based cure for devastating rare diseases and how will this contribute to the next wave of innovations? What are the implications for continued patient access to these high-cost, high-touch treatments – does the ROI calculation for rare diseases still add up?

Alexandra Moens

Alexandra Moens
Director, Product Marketing, H1

Arjen Lemmen_argenx

Arjen Lemmen
Vice President of Corporate Development & Strategy, argenx


Christine Clemson_Alberio Pharma

Christine Clemson, PhD MSCI
Senior Vice President, Global Head of Medical Affairs, Albireo Pharma, Inc.

Tom Schall

Tom Schall
President, CEO, Director, ChemoCentryx

Shephard Mpofu_Novartis

Shephard Mpofu
SVP, Chief Medical Officer,
Novartis Gene Therapies

Filip Van den Wyngaert

Filip Van den Wyngaert, MSc
Global Head for TTP,

12 PM - 1 PM ET

Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to treatment, particularly in solid tumors?

Michael Ringel, PhD

Michael Ringel, PhD
Managing Director and Senior Partner,
Global Leader, Growth & Innovation Analytics,
BCG Boston Consulting Group

Lusong Luo

Lusong Luo
Senior VP, External Innovation,

Kristen Hege

Kristen Hege
Senior Vice President, Early Clinical Development, Oncology/Hematology and Cell Therapy,
Bristol Myers Squibb

Gerold Meinhardt

Gerold Meinhardt, MD, PhD
Vice President, Asset & Portfolio Management,
Daiichi Sankyo

Robert Iannone

Robert Iannone, MD, MSCE
Executive Vice President, Global Head of Research and Development, Jazz Pharmaceuticals

1 PM - 2 PM ET

Given that many chronic diseases have an infectious origin, what learnings can be had by the most recent innovations in vaccine development technology in raising the bar on innovations to address the huge unmet need against conditions that kill millions?

Alexandra Moens

Alexandra Moens
Director, Product Marketing,

Ulrike K Buchwald

Ulrike K Buchwald, MD Dr. med MS
Executive Director, Global Clinical Development, Vaccine, Merck & Co., Inc.

Theresa Podrebarac

Theresa Podrebarac, MD, MSc
Senior Vice President, Clinical Development,
Horizon Therapeutics

David E. Anderson

David E. Anderson
Chief Scientific Officer,
VBI Vaccines, Inc.

Jaya L. Tiwari_XVIVO Perfusion

Jaya L. Tiwari
Vice President Clinical & Regulatory Affairs USA,
XVIVO Perfusion